Form 4 for ATRA Atara Biotherapeutics, Inc.
Accepted 2023-05-18 00:00:00 ET · period of report 2023-05-16 · accession 0001140361-23-025561 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-05-18 | 2023-05-16 | ATRA | Banard Charlene A. | EVP, Chief Technical Off | S - Sale | $2.04 | -19.0K | 276.0K | -6% | -$38.8K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-05-16 | S | D | 19,040 | $2.04 | 276,010 | D | — | — | (F2) The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on May 16, 2023 and May 17, 2023 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee. |